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15 ABSTRACT: Two new antibiotics, branimycins B (2) and C
16 (3), were produced by fermentation of the abyssal actino-
17 bacterium Pseudonocardia carboxydivorans M-227, isolated
18 from deep seawater of the Avileś submarine Canyon. Their
19 structures were elucidated by HRMS and NMR analyses.
20 These compounds exhibit antibacterial activities against a
21 panel of Gram-positive bacteria, including Corynebacterium
22 urealyticum, Clostridium perf ringens, and Micrococcus luteus, and
23 against the Gram-negative bacterium Neisseria meningitidis.
24 Additionally, branimycin B displayed moderate antibacterial
25 activity against other Gram-negative bacteria such as
26 Bacteroides f ragilis, Haemophilus inf luenzae, and Escherichia coli, and branimycin C against the Gram-positive Enterococcus
27 faecalis and methicillin-sensitive and methicillin-resistant Staphylococcus aureus.
28 The branimycins are compounds structurally related to a29 family of macrolide antibiotics known as nargenicins,
30 which exhibit antimicrobial activity mainly against Staph-
31 ylococcus aureus. Nargenicins and branimycins have a tricyclic
32 structure with either a 9- or 10-membered lactone ring and
33 contain a unique ether bridge. In 1977, the ﬁrst members of the
34 nargenicin family were isolated by Pﬁzer and Upjohn after the
35 aerobic fermentation of Nocardia argentinensis ATCC 31306.
36 This family of compounds and their antibacterial activity were
37 later patented,1 and the structure of one of them, nargenicin
38 A1, was elucidated.2 Although it showed antibacterial activity in
39 vitro, this was restricted to Gram-positive bacteria, particularly
40 methicillin-resistant S. aureus (MRSA). It was also described
41 that nargenicin A1 induces cell diﬀerentiation and can be used,
42 therefore, as a possible treatment for neoplastic diseases.
43 The ﬁrst branimycin (1) was isolated in 1998 from the
44 Actinomycete GW 60/1571 and its structure determined by the
45 Laatsch group through NMR analysis and comparison with
46 nargenicin A1.3 Since then, there was a great interest in this
47 new molecule, and a couple of organic syntheses have been
48 developed.4,5 Recently, the semisynthesis of branimycin
49 derivatives has been reported in a patent,6 demonstrating
50distinct antibiotic activities against Bacillus subtilis, S. aureus,
51E. coli, and Streptomyces viridochromogenes. The patent also
52reports that branimycin and derivatives exhibit in vivo activity in
53animal models of infection, eﬃcacious in treating infections in
54vivo, particularly via the oral route, increasing the interest of this
55family of natural products. Very interestingly, this year the
56conﬁguration of branimycin at position C-17 has been revised
57after X-ray crystallography and NMR studies in DMSO-d6.
7
58Oceans constitute more than 70% of our planet’s surface, of
59which 92−93% is deep sea (where 60% is covered by water
60more than 2000 m deep).8 The deep sea constitutes an extreme
61environment with high pressure, low temperature, darkness,
62high salinity, and low oxygen concentration, which has been
63revealed to be a worthy source for the discovery of new
64antibiotics.9
65Previous work in the Cantabrian Sea (Biscay Bay), Northeast
66Atlantic, has revealed that bioactive Actinobacteria, displaying a
67wide repertoire of chemically diverse molecules with diﬀerent
68antibiotic or antitumor activities, were isolated in the submarine
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69 Avileś Canyon up to 4700 m depth.10−13 One of these strains,
70 Pseudonocardia carboxydivorans M-227, isolated at 3000 m
71 depth in the water column, was further studied.13 We report
72 herein the discovery from cultures of this strain of two new
73 antibiotics of the branimycin family with antibacterial activity
74 against Gram-positive and Gram-negative clinical pathogens.
75 A culture of P. carboxydivorans M-227, isolated and identiﬁed
76 as previously described,13 in R5A medium was solid-phase
77 extracted and subsequently eluted with a MeOH gradient. After
78 bioassay-guided identiﬁcation of the active fractions these were
79 pooled and further puriﬁed by semipreparative reversed-phase
80 HPLC, leading to the isolation of the two compounds
81 responsible for the antibacterial activity. These natural products
82 were not included in our in-house dereplication library14 and
83 turned out to be new, being designated as branimycins B (2)
84 and C (3) based on their structure.
85 A protonated molecule at m/z 439.2326 together with the
86 presence of 23 signals in its 13C NMR spectrum assigned a
87 molecular formula of C23H34O8 to branimycin B (2). According
t1 88 to the analysis of its 1H, 13C (Table 1), and HSQC spectra,
89 these 23 carbon atoms accounted for the presence in the
90 molecule of one 1,2-disubstituted and one trisubstituted double
91 bond, one carbonyl group, ﬁve oxygenated methines, two
92 oxygenated methylenes, one nonprotonated carbon attached to
93 oxygen, six aliphatic methines, and one oxygenated and three
94 aliphatic methyl groups. Taking into account the seven degrees
95 of unsaturation that could be deduced from its molecular
96 formula and the three unsaturations due to the presence of two
97 double bonds and one carbonyl group, compound 1 must be a
g 98 tetracyclic molecule.
99 f1Correlations observed in the COSY spectrum (Figure 1)
100established the following spin systems: H-19−H-2−H-3−H-4−
Table 1. 1H and 13C NMR Spectra of Compounds 2 and 3 (1H 500 MHz, 13C 125 MHz, CDCl3)
2 3
position δC, type δH (J in Hz) δC, type δH (J in Hz)
1 179.6, C 179.5, C
2 46.1, CH 3.10, ddd (10.9, 9.6, 5.0) 46.1, CH 3.08, ddd (10.6, 9.6, 5.1)
3 51.5, CH 3.03, br d (9.6) 51.5, CH 3.02, br d (9.6)
4 126.4, CH 5.37, dd (9.8, 1.5) 126.4, CH 5.36, dd (9.7, 2.0)
5 131.5, CH 6.06, dd (9.8, 6.9, 1.3) 131.5, CH 6.05, dd (9.7, 6.9, 1.0)
6 38.6, CH 2.67, br d (6.9) 38.4, CH 2.71, br d (6.9)
7 84.0, CH 4.14, d (4.8) 83.8, CH 4.09, d (4.8)
8 72.4, CH 3.85, dd (4.8, 4.0) 71.5, CH 4.06, dd (4.8, 4.2)
9 35.7, CH 2.15, ddq (10.8, 4.0, 6.8) 40.1, CH 2.31, m
10 75.5, CH 3.56, m 71.9, CH 4.00, d (10.9)
11 48.6, CH 2.47, br s 48.1, CH 2.46, d (1.9)
12 88.4, C 88.5, C
13 133.4, C 133.8, C
14 138.9, CH 5.74, br d (7.6) 138.4, CH 5.70, br d (7.6)
15 32.2, CH 2.91, m 32.1, CH 2.90, m
16 79.8, CH 5.03, dd (9.9, 6.6) 79.8, CH 5.02, dd (10.0, 6.5)
17 69.3, CH 3.91, br d (9.8) 69.3, CH 3.90, br d (9.7)
18 64.2, CH2 3.81, dd (12.1, 2.5) 64.2, CH2 3.79, dd (12.2, 2.9)
3.71, br d (12.1) 3.70, br d (11.5)
19 73.5, CH2 3.55, m 73.5, CH2 3.55, dd (10.6, 8.6)
3.48, dd (11.2, 5.0) 3.47, dd (8.2, 4.8)
20 12.9, CH3 1.03, d (6.8) 73.3, CH2 3.76, dd (9.5, 4.6)
3.63, dd (9.5, 5.6)
21 16.8, CH3 1.68, s 16.8, CH3 1.70, s
22 15.1, CH3 1.26, d (6.9) 15.1, CH3 1.25, d (6.8)
23 59.2, CH3 3.31, s 59.1, CH3 3.30, s
24 59.1, CH3 3.35, s
Figure 1. Key COSY and HMBC correlations observed in the spectra
of branimycin B.
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101 H-5−H-6, H-7−H-8−H-9−H-10−H-11, and H-14 to H-18.
102 Additional cross-peaks in this spectrum also revealed the
103 attachment of the methyl groups CH3-20 to C-9 and CH3-22 to
104 C-15, and a low-intensity signal between H-6 and H-11 also
105 secured the connection between C-6 and C-11. Although no
106 correlation was observed in the COSY spectrum between H-6
107 and H-7, the linkage between their corresponding carbons was
108 based on HMBC correlations observed between H-7 and C-5,
109 C-6, and C-11, H-6 and C-4, C-5, C-8, C-10, C-11, and C-12,
110 and H-11 and C-5, C-6, and C-7 (Figure 1). A second ring
111 closure was established between C-3 and the nonprotonated
112 oxygenated carbon C-12 on the basis of HMBC cross-peaks
113 between H-2 and C-3 and C-12, H-4 and C-3 and C-12, and H-
114 11 and C-3 and C-12 (Figure 1). The third ring was due to the
115 existence of an ether bridge between C-7 and C-12 and was
116 evidenced by an intense HMBC correlation between H-7 and
117 C-12 (Figure 1) and by the deshielded chemical shift of carbons
118 C-7 and C-12 (84.0 and 88.4 ppm, respectively). The
119 placement of methyl CH3-21 at the quaternary oleﬁnic carbon
120 C-13 was revealed by HMBC correlations between the H-21
121 protons and C-12, C-13, and C-14 (Figure 1). C-2 was attached
122 to the carbonyl carbon C-1 at δC 179.6 ppm on the basis of
123 HMBC correlations from H-2, H-19, and H-3 to C-1 and an
124 additional correlation of this carbon to H-16, and the
125 deshielded chemical shift of the latter proton (δH 5.03 ppm)
126 indicated the existence of a lactone ring between C-1 and C-16,
127 accounting for the last unsaturation of the molecule. Finally, the
128 oxygenated methyl group C-23 present in the molecule was
129 placed at C-19 based on the presence of HMBC correlations
130 between the H-23 protons and C-19 and both H-19 protons
131 and C-23.
132 Once the planar structure of compound 1 was established, a
133 literature search revealed the existence of a molecule having the
134 same structural core, branimycin.3−5,7 A detailed comparison
135 between the NMR spectra of both molecules conﬁrmed their
136 similarity and established the diﬀerences in the structures as the
137 absence in compound 2 of the methyl ether at C-18, leaving a
138 free hydroxy group at this position, and the absence of the
139 methoxy group at C20 present in the structure of branimycin
140 (1). Interestingly, the above-mentioned patent6 reports a
141 branimycin analogue named baleomycin, which likewise lacks
142 the methoxyl group at C-20 but keeps the methyl ether at C-18,
143 being thus closely related to 2. On the other hand, a detailed
144 comparison of the NMR chemical shifts, multiplicities, and
145 NOESY correlations of 2 and branimycin7 also revealed the
146 same relative conﬁguration for both molecules, and the same
147 absolute conﬁguration could also be proposed on the basis of
148 the similar magnitudes and positive values of their speciﬁc
149 rotations ([α]25D +80, c 0.045, CHCl3, for branimycin).
5 The
150 absence of NOESY correlations between the H-18 protons and
151 the methyl H-22 is in favor of an (R)-C-17 conﬁguration as
152 recently described for branimycin.7
153 A molecular formula of C24H36O9 was determined for
154 compound 3 based on the existence of 24 signals in its 13C
155 NMR spectrum and ions detected in the HRESIMS spectrum
156 corresponding to the proton and ammonium adducts. Analysis
157 of its 1H and 13C NMR spectra revealed a close similarity with
158 those of compound 1, the most signiﬁcant diﬀerences being the
159 absence of the signal of the aliphatic methyl doublet group at
160 δH 1.03/δC 12.9 ppm, corresponding to CH3-20, present in the
161 spectra of 1, replaced by the presence of an extra oxygenated
162 methylene (δH 3.76 and 3.63/δC 73.3 ppm, CH2-20) and an
163 oxygenated methyl group at δH 3.35/δC 59.1 ppm (C-24) in
164those of 2. These changes were in agreement with the
165replacement of the C-20 methyl group in the structure of
166compound 2 by a methoxymethyl group in that of compound
1673. COSY correlations between H-9 at δH 2.31 ppm and both H-
16820 protons at δH 3.76 and 3.63 ppm and HMBC correlations
169between both H-20 protons and C-24 at δC 59.1 ppm and
170between H-24 at δH 3.35 ppm and C-20 at δC 73.2 ppm
171corroborated this proposal. Once again, the same absolute
172conﬁguration as in branimycin was proposed for branimycin C
173based on similar chemical shifts and multiplicities, NOESY
174correlations, and the magnitude and positive value of its speciﬁc
175rotation.
176Antimicrobial activities of compounds 2 and 3 were tested
177against a panel of human pathogens (Table S1). Some of these
178pathogens were isolated and identiﬁed in clinical microbiology
179laboratories from samples obtained from patients with clinical
180infections.
181 t2Table 2 shows the minimum inhibitory concentrations
182(MIC) obtained in these antibacterial tests. Both compounds
183exhibited moderate activities against Gram-positive bacteria
184(C. urealyticum, C. perf ringens, and M. luteus). In addition,
185compound 2 displayed moderate activities against E. faecalis
18610544, S. aureus ATCC 25923, S. aureus ATCC 6538P, and the
187methicillin resistant S. aureus (MRSA MB5393). Concerning
188Gram-negative bacteria, both compounds showed moderate
189activities against N. meningitidis. Compound 1 also displayed
Table 2. Minimum Inhibitory Concentrations (MIC, μg/
mL) against Clinic Bacterial Pathogens
microorganism 2 3
Gram-Positive
Clostridium perf ringens 103281 32 16
Corynebacterium urealyticum 1492 8 16
Enterococcus faecalis 10544 >64 64
Enterococcus faecalis ATCC 29212 >64 >64
Enterococcus faecalis ATCC 51299 >64 >64
Enterococcus faecium 10701 >64 >64
Micrococcus luteus ATCC 14452 1 16
Mycobacterium tuberculosis H37Rv >32 >32
Mycobacterium tuberculosis MDR-1 >32 >32
Mycobacterium tuberculosis MDR-2 >32 >32
Staphylococcus aureus ATCC 25923 >64 64
Staphylococcus aureus ATCC 6538P >128 32
Staphylococcus aureus ATCC 43300 >64 >64
Staphylococcus aureus 11497 >64 >64
Staphylococcus aureus MRSA MB5393 >160 20−40
Staphylococcus aureus MSSA MB2865 >160 80
Streptococcus pneumoniae 64412 >128 >128
Streptococcus pyogenes 81293 >128 >128
Gram-Negative
Acinetobacter baumannii MB5973 >80 >80
Bacteroides f ragilis ATCC 25285 32 128
Bacteroides f ragilis 61592 128 >128
Escherichia coli MB2884 >80 >80
Escherichia coli ESS 64 128
Haemophilus inf luenzae ATCC 49247 32 >64
Haemophilus inf luenzae 10996 >64 >64
Klebsiella pneumoniae ATCC 700603 >80 >80
Neisseria meningitidis 71327 32 64
Pseudomonas aeruginosa PAO1 >80 >80
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190 moderate bioactivity against B. f ragilis, H. inf luenzae ATCC
191 49247, and E. coli.
192 In conclusion, two new antibiotics, branimycins B (1) and C
193 (2), were isolated and characterized from the deep-sea-derived
194 P. carboxydivorans M-227 isolated from the water column at
195 3000 m depth in the Cantabrian Sea. These compounds
196 exhibited signiﬁcant inhibitory activities against diverse
197 pathogenic bacteria, both Gram-positive and Gram-negative
198 isolated at two main Hospitals (HUCA and Cabueñes) located
199 in the same geographical region where the microorganism was
200 isolated. Our ﬁndings constitute another example of the
201 relevance of marine natural products as a source of new
202 bioactive molecules and candidates for the treatment of
203 pathogenic antibiotic-resistant bacteria.
204 ■ EXPERIMENTAL SECTION
205 General Experimental Procedures. Optical rotations were
206 determined with a JASCO P-2000 polarimeter. IR spectra were
207 measured with a JASCO FT/IR-4100 spectrometer equipped with a
208 PIKE MIRacle single-reﬂection ATR accessory. NMR spectra were
209 recorded on a Bruker Avance III spectrometer (500 and 125 MHz for
210
1H and 13C NMR, respectively) equipped with a 1.7 mm TCI
211 MicroCryoProbe, using the signal of the residual solvent as internal
212 reference (δH 7.27 and δC 77.0 ppm for CDCl3). HRESIMS spectra
213 were acquired using a Bruker maXis QTOF mass spectrometer.
214 Semipreparative HPLC analyses and separations were conducted using
215 an Alliance chromatographic system equipped with a SunFire C18
216 column (10 μm, 10 × 250 mm). For UPLC analysis an Acquity UPLC
217 equipped with a BEH C18 column (1.7 μm, 2.1 × 100 mm) was used.
218 Microorganism and Fermentation Conditions. Strain M-227
219 was isolated from a deep-water sample collected from the Cantabrian
220 Sea at a depth of 3000 m as previously described.13 A seed culture was
221 prepared by inoculating spores of this strain in 50 mL of GCM
222 medium (1.5% glucose, 2% soy peptone, 0.15% yeast extract, 1%
223 MOPS, 0.01% CaCl2, pH 6.7) in a 250 mL Erlenmeyer ﬂask. This
224 culture was incubated in an orbital shaker for 4 days at 28 °C and 250
225 rpm and used to inoculate (at 2%, v/v) 20 × 250 mL Erlenmeyer
226 ﬂasks, each containing 50 mL of R5A medium, which were incubated
227 for 10 days in the above conditions.
228 Bioassay-Guided Isolation and Puriﬁcation. The cultures were
229 centrifuged, the pellets were discarded, and the supernatants were
230 ﬁltered and applied to a solid-phase extraction cartridge (Sep-Pak Vac
231 C18, 10 g). The retained material was eluted with a mixture of MeOH
232 and 0.05% triﬂuoroacetic acid (TFA) in H2O. A linear gradient from 0
233 to 100% MeOH in 60 min, at 10 mL/min, was used. Fractions were
234 collected every 5 min, and their antibiotic activity was detected by disk
235 diﬀusion bioassay, using Micrococcus luteus as indicator microorganism.
236 Most of the activity was located in the two fractions taken between 15
237 and 25 min, which were evaporated in vacuo, and the dry material was
238 subsequently redissolved in 3 mL of DMSO and MeOH (1:1).
239 Aliquots (100 μL) of these active fractions were chromatographed in a
240 SunFire C18 column (10 μm, 10 × 250 mm), with CH3CN and 0.05%
241 TFA in H2O as solvents. Elution was performed with a linear gradient
242 from 20% to 100% CH3CN in 10 min, at 5 mL/min, and the eluate
243 was collected in fractions taken every 10 s. Once more, the antibiotic
244 activity in these fractions was located by bioassay, and subsequently all
245 the active material was chromatographed in multiple injections in the
246 same conditions. The collected active fractions corresponding to the
247 same retention times were pooled, diluted 4-fold with H2O, desalted,
248 and concentrated by solid-phase extraction (Sep-Pak C18). UPLC
249 analysis of these fractions15 indicated that the antibiotic activity
250 appeared to correlate with the presence of two major peaks. These
251 peaks were further puriﬁed using the same column and solvents, but
252 this time an isocratic elution with 20% CH3CN was employed. The
253 puriﬁed compounds were diluted with H2O and solid-phase extracted
254 as above. They were ﬁnally dissolved in a mixture of tert-butanol and
255 H2O (1:1) and lyophilized. The resulting yields were 58.6 mg of 1 and
256 61.7 mg of 2 from a 1 L culture.
257Branimycin B (2): white, amorphous solid; [α]20D +110 (c 0.1,
258CHCl3); IR (ATR) νmax 3419, 3038, 2961, 2929, 2878, 2832, 1719,
2591457, 1378, 1248, 1147, 1117, 1082, 1030, 984, 944, 890 cm−1; 1H and
260
13C NMR data, Table 1; HRESIMS m/z 456.2596 [M + NH4]
+ (calcd
261for C23H38NO8, 456.2592), 439.2326 [M + H]
+ (calcd for C23H35O8,
262439.2326), 421.2222 [M − H2O + H]+ (calcd for C23H33O7,
263421.2221).
264Branimycin C (3): white, amorphous solid; [α]20D +100 (c 0.1,
265CHCl3); IR (ATR) νmax 3422, 3038, 2961, 2931, 2879, 2833, 1722,
2661457, 1386, 1248, 1140, 1118, 1083, 1030, 979, 945, 889 cm−1; 1H and
267
13C NMR data, Table 1; HRESIMS m/z 486.2709 [M + NH4]
+ (calcd
268for C24H40NO9, 486.2698), 469.2432 [M + H]
+ (calcd for C24H37O9,
269469.2432), 451.2333 [M − H2O + H]+ (calcd for C24H35O8,
270451.2326).
271Antimicrobial Activities of Compounds 2 and 3 against
272Clinic Pathogens. Antimicrobial activities of compounds 2 and 3
273were evaluated, and the MICs were determined against a panel of
274human pathogens (Table S1). Some of these pathogens were isolated
275and identiﬁed in clinical microbiology laboratories from samples
276obtained in patients with clinical infections. Mueller-Hinton agar
277(Biomedics) was the culture medium used in bioassays against E. coli,
278S. aureus, E. faecalis, E. faecium, M. luteus, and H. inf luenzae, being
279supplemented according to the CLSI conditions for S. pneumoniae,
280S. pyogenes, and N. meningitidis. Trypticasein soy agar w/5% sheep
281blood (DIFCO) was used for C. urealyticum. Brucella Broth (Sigma)
282supplemented with hemin (5 μg/mL), vitamin K1 (1 μg/mL), and
283lysed horse blood (5% v/v) was used for B. f ragilis and C. perf ringens.
284Assays against methicillin-resistant S. aureus MRSA MB5393 and
285methicillin-sensitive S. aureus MSSA MB2865 were performed by
286mixing a volume of 90 μL of the appropriate diluted inocula with 8.4
287μL of medium (LB or BHI) and 1.6 μL of each compound dilution.
288Assays were performed in triplicate using 2-fold serial dilutions from
289160 to 0.31 μg/mL. Vancomycin (32 to 4 μg/mL) and penicillin G
290(0.312 to 0.039 μg/mL) were used as positive controls for MRSA and
291MSSA, respectively. Amphotericin B (16 to 0.25 μg/mL) was used as
292negative control in both cases. Antimicrobial activity tests against
293A. baumannii MB5973, E. coli MB2884, and P. aeruginosa PAO1 were
294performed as previously described.16
295For the rest of the Gram-positive and Gram-negative bacteria, the
296antimicrobial assays were performed according to CLSI performance
297standards.17 For Mycobacterium tuberculosis, susceptibility testing was
298done in Middlebrook 7H10 agar medium supplemented with 10%
299OADC and 0.5% glycerol according to the agar proportion method for
300slowly growing mycobacteria.18
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(14)373 Peŕez-Victoria, I.; Martín, J.; Reyes, F. Planta Med. 2016, 82,
374 857−871.
(15)375 Braña, A. F.; Rodríguez, M.; Pahari, P.; Rohr, J.; García, L. A.;
376 Blanco, G. Arch. Microbiol. 2014, 196, 345−55.
(16)377 Audoin, C.; Bonhomme, D.; Ivanisevic, J.; de la Cruz, M.;
378 Cautain, B.; Monteiro, M. C.; Reyes, F.; Rios, L.; Perez, T.; Thomas,
379 O. P. Mar. Drugs 2013, 11, 1477−1489.
(17)380 CLSI. Performance Standards for Antimicrobial Susceptibility
381 Testing, Twenty-Fourth Informational Supplement. CLSI document
382 M100-S24; Clinical and Laboratory Standards Institute: Wayne, PA,
383 2014.
(18)384 CLSI. Susceptibility Testing of Mycobacteria, Nocardiae, and Other
385 Aerobic Actinomycetes, Approved Standard, Second ed. CLSI document
386M-24-A2; Clinical and Laboratory Standards Institute: Wayne, PA,
3872011.
Journal of Natural Products Note
DOI: 10.1021/acs.jnatprod.6b01107
J. Nat. Prod. XXXX, XXX, XXX−XXX
E
